Perkovic, V; Jardine, MJ; Neal, B; Bompoint, S; Heerspink, HJL; Charytan, DM; Edwards, R; ... CREDENCE Trial Investigators, .; + view all Perkovic, V; Jardine, MJ; Neal, B; Bompoint, S; Heerspink, HJL; Charytan, DM; Edwards, R; Agarwal, R; Bakris, G; Bull, S; Cannon, CP; Capuano, G; Chu, P-L; de Zeeuw, D; Greene, T; Levin, A; Pollock, C; Wheeler, DC; Yavin, Y; Zhang, H; Zinman, B; Meininger, G; Brenner, BM; Mahaffey, KW; CREDENCE Trial Investigators, .; - view fewer (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine , 380 (24) pp. 2295-2306. 10.1056/NEJMoa1811744.

Preview

Text Wheeler_nejmoa1811744.pdf - Published Version Download (465kB) | Preview

Abstract

BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS: In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS: The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).

Downloads since deposit

Loading...

314Downloads

Download activity - last month

Export as JSONXMLCSV

Loading...

Download activity - last 12 months

Export as CSVXMLJSON

Loading...

Downloads by country - last 12 months

Export as JSONCSVXML

1.	China	33
2.	United States	7
3.	Germany	3
4.	United Kingdom	1
5.	Turkey	1
6.	Brazil	1
7.	Japan	1

102550all

Archive Staff Only

View Item